Home ›
Drugs ›
Antipsychotics ›
Industry payments by company
Antipsychotics
Industry payments by company
10 rows
Summary of public sources, not medical advice. This page is an automated summary of public information from the FDA, the National Library of Medicine (DailyMed) and CMS Medicare data. It has not been reviewed by a doctor or pharmacist, may be incomplete, out of date or wrong, and does not list every use, dose, warning, interaction or side effect. Do not start, stop or change any medicine, or take a pill you cannot identify, based on this page: ask your doctor or pharmacist and read the official label. In an emergency call 911; for possible poisoning call Poison Control at 1-800-222-1222. Use of this page is subject to our Medical and Data Disclaimer and Terms of Use .
Company Payments, 2025 Clinicians paid
Alkermes, Inc. $10.2M 37,687 Teva Pharmaceuticals USA, Inc. $5.7M 13,377 Otsuka America Pharmaceutical, Inc. $3.2M 13,689 Lundbeck LLC $164,139 2,647 H. Lundbeck A S $53,330 3 Otsuka Pharmaceutical Development & Commercialization, Inc. $33,862 191 Janssen Pharmaceuticals, Inc $2,830 63 AstraZeneca Pharmaceuticals LP $1,333 53 E.r. Squibb & Sons, L.l.c. $832 42 Eli Lilly and Company $69 1
← Back to Antipsychotics
Sources: CMS Medicare Part D Prescribers 2024; CMS Open Payments 2025 (general payments; a payment is not evidence of wrongdoing); FDA enforcement reports (openFDA).